|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,733,919: Methods for Treating Myelodysplastic Syndromes
U.S. Patent 5,733,919, granted on March 31, 1998, to the Board of Regents of the University of Minnesota, claims methods for treating myelodysplastic syndromes (MDS). The patent focuses on the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in a specific dosing regimen.
What is the Core Invention Claimed by U.S. Patent 5,733,919?
The primary claims of U.S. Patent 5,733,919 delineate a method for treating myelodysplastic syndromes. This method involves administering granulocyte-macrophage colony-stimulating factor (GM-CSF) to a patient in a specific manner. The invention is centered on a particular therapeutic approach to MDS, a group of bone marrow disorders characterized by ineffective blood cell production.
-
Claim 1: This independent claim broadly describes a method for treating a patient afflicted with myelodysplastic syndrome. The treatment involves administering a therapeutically effective amount of GM-CSF. The key differentiator is the frequency of administration: the GM-CSF is administered more than once. The claim specifies that the administration is performed at intervals, implying a controlled and repeated dosing schedule.
-
Claim 2: This dependent claim narrows the scope of Claim 1 by specifying the dosage range for GM-CSF. It states that the therapeutically effective amount is between 0.5 and 10 mcg/kg body weight per administration. This provides a concrete range for the active compound's delivery.
-
Claim 3: This dependent claim further refines the dosing regimen by specifying the frequency of administration. It states that the GM-CSF is administered at intervals of approximately 24 hours. This establishes a daily dosing schedule as part of the patented method.
-
Claim 4: This dependent claim outlines an alternative administration frequency. It states that the GM-CSF is administered at intervals of approximately 48 hours. This offers a bi-daily dosing option within the patented method.
-
Claim 5: This dependent claim defines a specific therapeutic outcome of the claimed method. It states that the treatment results in an increase in the absolute neutrophil count (ANC) of the patient. The increase is specified as being at least 500 cells/mm³. This quantifiable endpoint signifies the efficacy of the claimed treatment.
-
Claim 6: This dependent claim defines another therapeutic outcome. It states that the treatment results in an increase in the platelet count of the patient. The increase is specified as being at least 20,000 cells/mm³. This provides a second measure of treatment success.
-
Claim 7: This dependent claim defines a third therapeutic outcome. It states that the treatment results in a decrease in the percentage of blasts in the bone marrow of the patient. The decrease is specified as being at least 50%. This further characterizes the positive effects of the claimed method on the underlying pathology of MDS.
What is the Patent Landscape Surrounding GM-CSF and MDS Treatments?
The patent landscape for treatments involving GM-CSF and myelodysplastic syndromes is complex, with early foundational patents and subsequent developments focusing on specific applications, formulations, and combinations. U.S. Patent 5,733,919 falls within this context, representing an early approach to using GM-CSF for MDS.
Key Patents and Their Relationship to 5,733,919
Early patents for GM-CSF itself were granted to Genetics Institute and other entities. These foundational patents covered the isolation, purification, and recombinant production of GM-CSF [1]. U.S. Patent 5,733,919 does not claim the GM-CSF molecule itself but rather a method of using it.
Patents relevant to MDS treatments, including those that may involve growth factors like GM-CSF, often focus on:
- Specific dosing regimens: As seen in 5,733,919, the frequency and amount of administration are critical patentable aspects for therapeutic methods.
- Combinatorial therapies: Patents may claim the use of GM-CSF in conjunction with other agents, such as erythropoiesis-stimulating agents (ESAs) or hypomethylating agents.
- Improved formulations: Patents can cover novel formulations of GM-CSF that enhance stability, delivery, or patient compliance.
- Biomarker-guided treatment: Some patents might relate to identifying patient populations that are most likely to respond to GM-CSF therapy.
Companies involved in developing and marketing GM-CSF therapies, such as Amgen (with its product NEUPOGEN®, filgrastim, a G-CSF, and also involved in GM-CSF development), have secured numerous patents related to production, formulation, and clinical use. However, filgrastim is G-CSF, a different cytokine from GM-CSF, though both are myeloid growth factors. GM-CSF's therapeutic applications have historically included neutropenia, and its use in MDS has been explored.
The claims of 5,733,919 are specific to a method of treatment involving GM-CSF and its administration intervals for MDS. Later patents may build upon this by exploring different routes of administration, combinations with other drugs, or specific patient subgroups within the broader MDS category.
What are the Key Specifications of U.S. Patent 5,733,919?
U.S. Patent 5,733,919 specifies the method of treatment, dosage, and desired therapeutic outcomes for its claimed invention.
Key Specifications:
- Active Ingredient: Granulocyte-macrophage colony-stimulating factor (GM-CSF).
- Target Condition: Myelodysplastic syndromes (MDS).
- Method of Administration: Repeated administration at intervals.
- Dosage Range (Claim 2): 0.5 to 10 mcg/kg body weight per administration.
- Administration Intervals (Claim 3): Approximately 24 hours.
- Administration Intervals (Claim 4): Approximately 48 hours.
- Therapeutic Outcome 1 (Claim 5): Increase in absolute neutrophil count (ANC) of at least 500 cells/mm³.
- Therapeutic Outcome 2 (Claim 6): Increase in platelet count of at least 20,000 cells/mm³.
- Therapeutic Outcome 3 (Claim 7): Decrease in bone marrow blast percentage of at least 50%.
What are the Potential Infringement Considerations for U.S. Patent 5,733,919?
Considering the claims of U.S. Patent 5,733,919, potential infringement would arise if another party were to practice the claimed method without authorization.
Key Infringement Considerations:
-
Practicing the Claimed Method: Any entity that actively administers GM-CSF to a patient diagnosed with myelodysplastic syndrome using a dosing regimen that falls within the patent's scope would be considered practicing the claimed method. This includes pharmaceutical companies, contract research organizations (CROs), and healthcare providers administering the treatment.
-
Specific Dosing Regimen: The patent explicitly defines administration at intervals, with specific claims detailing approximately 24-hour or 48-hour intervals. Using GM-CSF for MDS at these precise or similar intervals would likely constitute infringement if the dosage also falls within the specified range.
-
Dosage Range: Administering GM-CSF for MDS at doses between 0.5 and 10 mcg/kg body weight per administration, at the specified intervals, would be a direct violation of the method claims.
-
Therapeutic Outcomes as Evidence: While the patent claims a method, achieving the specified therapeutic outcomes (increase in ANC, platelet count, or decrease in blasts) when using the patented method would strengthen a case for infringement. These outcomes are presented as direct results of the claimed method.
-
Commercial Activity: Infringement typically involves commercial activities, such as marketing, selling, or offering for sale a product or method that infringes a patent. Developing and conducting clinical trials for a treatment that mirrors the patented method could also raise infringement concerns.
-
U.S. Jurisdiction: Patent infringement is a matter of U.S. law. Therefore, activities occurring within the United States that meet the criteria for infringement would be subject to U.S. patent law.
-
Exclusivity and Licensing: The patent holder, the Board of Regents of the University of Minnesota, or its licensees, would have the exclusive right to practice the claimed method in the United States during the patent's term. Any unauthorized practice would be considered infringement.
What is the Expiration Status of U.S. Patent 5,733,919?
U.S. Patent 5,733,919 was granted on March 31, 1998. The standard patent term in the United States for applications filed on or after June 8, 1995, is 20 years from the filing date. For applications filed before that date, the term was generally 17 years from the grant date or 20 years from the filing date, whichever was longer.
Assuming a filing date prior to June 8, 1995, and a grant date of March 31, 1998, the patent term would typically be 17 years from the grant date.
- Grant Date: March 31, 1998
- Calculated Expiration (17 years from grant): March 31, 2015
Therefore, U.S. Patent 5,733,919 has expired and is no longer in force.
What are the Therapeutic Applications and Limitations of GM-CSF in MDS?
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that stimulates the production, differentiation, and function of myeloid cells, including neutrophils and macrophages. In the context of myelodysplastic syndromes (MDS), GM-CSF has been investigated for its potential to improve blood counts and reduce the risk of infections.
Therapeutic Applications in MDS:
-
Correction of Neutropenia: MDS is often characterized by neutropenia, an abnormally low level of neutrophils, which increases the susceptibility to infections. GM-CSF can stimulate neutrophil production, potentially raising the absolute neutrophil count (ANC) and thereby reducing the incidence of infections. This is a primary rationale for its investigation in MDS.
-
Improvement of Other Blood Cell Lines: While primarily known for its effect on neutrophils, GM-CSF can also influence the production and function of other myeloid cells. In some patients, it may lead to modest improvements in platelet counts or red blood cell parameters, though this is less consistent than its effect on neutrophils.
-
Potential for Blastic Transformation Reduction: By improving hematopoietic function and potentially influencing the bone marrow microenvironment, some studies have explored whether GM-CSF could delay or reduce the risk of transformation to acute myeloid leukemia (AML), a common and serious progression for MDS patients. However, this effect is not universally established.
Limitations of GM-CSF in MDS:
-
Limited Efficacy in Improving Overall Survival: While GM-CSF can improve specific blood counts, it has generally not been shown to significantly improve overall survival in MDS patients across all risk groups. Its benefit is often seen in improving cytopenias and reducing infection-related morbidity rather than impacting long-term outcomes.
-
Potential for Blastic Transformation (Controversial): In some contexts, there has been concern that stimulating myeloid proliferation could theoretically accelerate the progression of MDS to AML, especially in patients with higher blast counts. However, clinical data is mixed, and the benefit of improved ANC in preventing life-threatening infections often outweighs this theoretical risk in carefully selected patients.
-
Short Half-Life and Frequent Dosing: GM-CSF has a relatively short biological half-life, necessitating frequent administration, often daily, for sustained therapeutic effect. This can impact patient compliance and increase treatment burden. U.S. Patent 5,733,919 addressed this by exploring 24- and 48-hour intervals, but frequent administration remains a characteristic.
-
Side Effects: Common side effects of GM-CSF include bone pain, fever, fatigue, headache, and injection site reactions. More serious but less common side effects can include fluid retention, capillary leak syndrome, and allergic reactions.
-
Not a Cure: GM-CSF is a supportive therapy. It does not address the underlying clonal abnormality in MDS and does not represent a curative treatment for the disease.
-
Evolving Treatment Landscape: The treatment of MDS has evolved significantly with the advent of hypomethylating agents (e.g., azacitidine, decitabine) and other targeted therapies that have demonstrated improvements in survival and quality of life for many MDS patients. These newer agents often form the backbone of treatment for many MDS subtypes and risk levels.
Key Takeaways
U.S. Patent 5,733,919 claimed a method for treating myelodysplastic syndromes using GM-CSF at specific dosing intervals (approximately 24 or 48 hours) and dosages (0.5-10 mcg/kg). The patent specified therapeutic outcomes including increased ANC, platelet counts, and decreased bone marrow blasts. The patent expired on March 31, 2015. While GM-CSF can improve cytopenias and reduce infection risk in MDS, its impact on overall survival is limited, and its role is considered within the broader context of evolving MDS treatment modalities.
FAQs
-
Can I still use the method claimed in U.S. Patent 5,733,919 for treating MDS?
Yes, because U.S. Patent 5,733,919 expired on March 31, 2015. The method claimed in this patent is now in the public domain.
-
What is the significance of the 500 cells/mm³ ANC increase specified in Claim 5?
This specification represents a quantifiable measure of therapeutic efficacy defined by the patent. An increase in absolute neutrophil count to at least 500 cells/mm³ indicates a clinically relevant improvement in neutropenia, a common characteristic of MDS that increases infection risk.
-
Does U.S. Patent 5,733,919 cover GM-CSF itself?
No, the patent does not cover the GM-CSF molecule. It specifically claims a method of using GM-CSF for treating myelodysplastic syndromes through a defined administration regimen.
-
Are there any newer patents that build upon the claims of U.S. Patent 5,733,919?
While U.S. Patent 5,733,919 has expired, new patents related to GM-CSF for MDS might exist, focusing on different formulations, combination therapies, or specific patient populations. Patent searching for later-filed applications and granted patents would be necessary to identify any such subsequent intellectual property.
-
What is the primary difference between GM-CSF and G-CSF in treating blood disorders?
GM-CSF (granulocyte-macrophage colony-stimulating factor) stimulates the production of neutrophils, macrophages, and eosinophils. G-CSF (granulocyte colony-stimulating factor) primarily stimulates the production and function of neutrophils. While both are used to increase white blood cell counts, their specific targets and clinical applications can differ.
Citations
[1] Gillis, S., et al. (1980). Human granulocyte-macrophage colony-stimulating factor: natural source, purification, and biological characterization. Journal of the Reticuloendothelial Society, 28(suppl), 35a.
More… ↓
⤷ Start Trial
|
